Posts

OneDayAdvisor Master Guide: Investing, AI, Technology & Health

By -
Image
OneDayAdvisor Master Guide & Site Index OneDayAdvisor is a research and decision platform covering money, investing, artificial intelligence, technology, healthcare and consumer decision-making. This master guide connects the site's major research areas, tools and practical guides in one place. Last updated:  October 2026  |  Purpose: Master pillar + site index Start here. OneDayAdvisor is designed around a simple idea: better decisions begin with better information. Instead of treating every topic as an isolated article, this site organizes research around the decision a reader is trying to make, the evidence needed to evaluate it, the risks involved and the tools available to help. On this page What Is OneDayAdvisor? Start Here: Choose Your Decision The OneDayAdvisor Knowledge Architecture Money & Investing ...
Post a Comment
Read more

Eli Lilly vs Novo Nordisk — The GLP‑1 Market Showdown (2026 Perspective)

By -
Image
By One Day Advisor Editorial Team · Last updated: November 2026  · Originally published November 2025 Quick Answer: Who is winning the GLP-1 market? Eli Lilly leads Novo Nordisk in GLP-1 medicines as of the October 29, 2026 close. Lilly's market value is about $1.14 trillion ($1,279.14 a share), roughly 6.6 times Novo's $172 billion, after Q3 revenue rose 39% to $24.4 billion.  Lilly reported Q3 2026 revenue of $24.4 billion, up 39% year over year, driven primarily by Mounjaro and Zepbound.   Novo’s adjusted sales rose 4%, led by the Wegovy pill (DKK 5.39 billion), and its outlook now spans −2% to +2%.  The key questions are valuation, price erosion, Medicare policy and pipeline timing, including CagriSema’s FDA decision and retatrutide’s 2027 filing, not whether demand exists. [28] [29] Disclosures Not investment or medical advice. This article is educational. Stock prices, clinical ...
Post a Comment
Read more